Hangzhou Yuannang Biotechnology Co., Ltd. has recently wrapped up a Series A funding round, raising nearly 100 million yuan. This funding initiative was spearheaded by Hetang Venture Capital, with contributions also coming from institutions like Zheshang Venture Capital. The funds raised will be predominantly channeled into accelerating the clinical deployment of its flagship product, the 'Gu02 Fragmented Bone Adhesive'. This innovative product boasts the ability to swiftly adhere in blood-soaked conditions and is entirely biodegradable. As a firm committed to the research and development of musculoskeletal regenerative medical materials, Yuannang Biotech adheres to a 'clinical-research-clinical' R&D framework and has successfully pioneered numerous cutting-edge implant materials. These achievements encompass the 'first-of-its-kind in China' PRP patch preparation kit and porcine-derived bone repair materials that effectively sidestep immune rejection challenges. Notably, the 'Gu02 Fragmented Bone Adhesive' excels at seamlessly fusing fractured bone segments, diminishing the reliance on metallic internal fixation, and is poised for extensive utilization across a range of clinical settings for hard tissue adhesion in the foreseeable future.